WallStSmart

Masimo Corporation (MASI)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 4120% more annual revenue ($65.77B vs $1.56B). MRK leads profitability with a 13.6% profit margin vs 4.9%. MASI appears more attractively valued with a PEG of 4.83. MASI earns a higher WallStSmart Score of 56/100 (C).

MASI

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 8.0
Piotroski: 6/9Altman Z: 3.43

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MASIUndervalued (+4.8%)

Margin of Safety

+4.8%

Fair Value

$141.85

Current Price

$178.82

$36.97 discount

UndervaluedFair: $141.85Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MASI3 strengths · Avg: 9.3/10
EPS GrowthGrowth
214.4%10/10

Earnings expanding 214.4% YoY

Altman Z-ScoreHealth
3.4310/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
23.6%8/10

Strong operational efficiency at 23.6%

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

MASI4 concerns · Avg: 2.8/10
Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Profit MarginProfitability
4.9%3/10

4.9% margin — thin

PEG RatioValuation
4.832/10

Expensive relative to growth rate

P/E RatioValuation
44.4x2/10

Premium valuation, high expectations priced in

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MASI

The strongest argument for MASI centers on EPS Growth, Altman Z-Score, Operating Margin.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : MASI

The primary concerns for MASI are Price/Book, Profit Margin, PEG Ratio. A P/E of 44.4x leaves little room for execution misses. Thin 4.9% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

MASI carries more volatility with a beta of 1.10 — expect wider price swings.

MASI is growing revenue faster at 8.5% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MASI scores higher overall (56/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Masimo Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Masimo Corporation develops, manufactures and markets non-invasive monitoring technologies and hospital automation solutions globally. The company is headquartered in Irvine, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?